

Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	09/475,649
Filing Date	12/30/1999
First Named Inventor	Bhat, Vinayak
Group Art Unit	3673
Examiner Name	Not Assigned
Attorney Docket Number	03764.P001

RECEIVED

MAR 21 2001

TO 3600 MAIL ROOM

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SK		R. RIESSEN et al., "Prospects for Site Specific Delivery of Pharmacological and Molecular Therapies," J. Am. Col. Card., April 1994, pgs 1234-1244, Vol 23:5	
SK		Y. AKAMO, et al., "Chemotherapy Targeting Regional Lymph Nodes By Gastric Submucosal Injection of Liposomal Adriamycin in Patients With Gastric Carcinoma," Jpn. J. Cancer Research, June 1994, pgs 652-658, Vol. 85:6,	
SK		E. NABEL, et al., "Safety and Toxicity of Catheter Gene Delivery to the Pulmonary Vasculature in a Patient With Metastatic Melanoma," Hum. Gene Ther., Sept 1994, pgs 1089-1094, Vol. 5:9, Mary Ann Liebert	
		Goodman and Gilman's The Pharmacological Basis of Therapeutics, 1995, pgs 103-1673, 9th ed. no copy	
		The United States Pharmacopoeia, The National Formulary, 1995, USP-23-NF-18 no copy	
SK		B. RATNER, et al., Biomaterials Science: Introduction to Materials and Medicine, 1996, pgs 68-69, Academic Press	
I		I. RAAD, et al., "Silver Iontophoretic Catheter: A Prototype of a Long-term Antiinfective Vascular Access Device," J. Infect. Dis., Feb. 1996, pgs 495-498, Vol. 173:2	
		H. OHIGASHI M.D., et al., "A New Method of Intra-Arterial Regional Chemotherapy With More Selective Drug Delivery For Locally Advanced Pancreatic Cancer," Hepatogastroenterology, Mar. Apr. 1996, pgs. 338-345, Vol. 43:8	
		E.H. TAN, et al., "5-Fluorouracil Continuous Infusion In Metastatic Colorectal Cancer," Ann. Acad. Med. Singapore, Sept. 1996, pgs 748-751, Vol. 25:5	
		D. STEPHAN, et al., "A New Cationic Liposome DNA Complex Enhances the Efficiency of Arterial Gene Transfer In Vivo," Hum. Gene Ther., Oct. 1, 1996, pgs 1803-1812, Vol. 7:15, Mary Ann Liebert	
SK		D. BRIEGER et al., "Local Drug Delivery Systems and Prevention of Restenosis," Cardiovasc. Res., 1997, pgs. 405-413, Vol. 35, Elsevier Science B.V.	

Examiner
Signature

Sharon Kennedy

Date


Considered

June 13, 2002

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/088 (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO			Compleat if Kn wn		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/475,649	
			Filing Date	12/30/1999	
			First Named Inventor	Bhat, Vinayak	
			Group Art Unit	3673	
			Examiner Name	Not Assigned	
Sheet	3	of	3	Attorney Docket Number	03764.P001

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SK		S. BAILEY, "Local Drug Delivery: Current Applications," Progress in Cardiovascular Diseases, Sept/Oct 1997, pgs. 183-204, Vol. 40:2	
SK		V. BHAT, et al., "Improving Endothelial Cell Adhesion to Vascular Graft Surfaces: Clinical Need and Strategies," J. Biomat. Sci. Polymer. Edn., 1998, pgs 1117-1135, Vol. 9:11	
SK		STURGEON, C. M. "The Synthesis of Polysaccharide Derivatives," Carbohydrate Chemistry, 1988, Chapter 13, Oxford University Press, New York	
SK		V. BHAT, et al., "Using Avidin-Mediated Binding To Enhance Initial Endothelial Cell Attachment and Spreading," J. Biomed. Mater. Res., April 1998, pgs 57-65, Vol. 40:1, John Wiley & Sons	
SK		V. BHAT, et al., "Fibronectin and Avidin-Biotin as a Heterogeneous Ligand System For Enhanced Endothelial Cell Adhesion," J. of Biomed. Mater. Res., Sept. 5, 1998, pgs 337-385, Vol. 41:3, John Wiley & Sons	
		The Physician's Desk Reference, 1999, 49th ed. - no copy	
		Drug Facts and Comparisons, 2000, 4th ed no copy	

Examiner Signature	<i>Sharon Kennedy</i>	Date Considered	<i>June 13, 2002</i>
--------------------	-----------------------	-----------------	----------------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.